STELLAR-009: Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab
Condition: Solid Tumors
Sponsor: Exelixis
Full Title
Protocol XL092-009: A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors
Study Treatment
Zanzalintinib, an oral RTK inhibitor
AB521, an oral HIF-2α inhibitor
Eligibility/Info
- Cytologically or histologically confirmed inoperable locally advanced or metastatic solid tumor
- Has previously received treatment with all appropriate standard of care therapies
Contact
For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: 631-675-5075.
